Arrowhead Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Arrowhead Pharmaceuticals' es Chris Anzalone , nombrado en Dec 2007, tiene una permanencia de 16.33 años. compensación anual total es $9.92M, compuesta por 9.1% salario y 90.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 3% de las acciones de la empresa, por valor de $81.25M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 13.4 años, respectivamente.
Información clave
Chris Anzalone
Chief Executive Officer (CEO)
US$9.9m
Compensación total
| Porcentaje del salario del CEO | 9.1% |
| Permanencia del CEO | 16.3yrs |
| Participación del CEO | 3.0% |
| Permanencia media de la dirección | 5.8yrs |
| Promedio de permanencia en la Junta Directiva | 13.4yrs |
Actualizaciones recientes de la dirección
Recent updates
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03
Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05Arrowhead Pharma: We Can Afford To Wait For More Proof
Jun 28Companies Like Arrowhead Pharmaceuticals (NASDAQ:ARWR) Can Afford To Invest In Growth
Jun 18Arrowhead Pharma: Know Pros' Calcs For Coming Stock Prices
Apr 14Are Investors Undervaluing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) By 46%?
Feb 08Arrowhead: 2021 Was A Struggle Valuation Wise - Things May Get Worse In 2022
Jan 26Accumulate Arrowhead For Its RNAi Pipeline
Jan 17Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
| Jun 30 2019 | n/a | n/a | US$46m |
| Mar 31 2019 | n/a | n/a | US$10m |
| Dec 31 2018 | n/a | n/a | -US$29m |
| Sep 30 2018 | US$2m | US$643k | -US$54m |
| Jun 30 2018 | n/a | n/a | -US$54m |
| Mar 31 2018 | n/a | n/a | -US$44m |
| Dec 31 2017 | n/a | n/a | -US$35m |
| Sep 30 2017 | US$2m | US$616k | -US$34m |
Compensación vs. Mercado: La compensación total de Chris($USD9.92M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.59M).
Compensación vs. Ingresos: La compensación de Chris ha sido consistente con los resultados de la empresa en el último año.
CEO
Chris Anzalone (54 yo)
16.3yrs
Permanencia
US$9,918,093
Compensación
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 16.3yrs | US$9.92m | 3% $ 82.2m | |
| Chief Financial Officer | 14.2yrs | US$3.12m | 0.19% $ 5.2m | |
| COO, General Counsel & Secretary | 9.3yrs | US$3.31m | 0.23% $ 6.3m | |
| Chief of Discovery & Translational Medicine | no data | US$3.05m | 0.17% $ 4.5m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | sin datos | sin datos | |
| Head of Investor Relations & VP | no data | sin datos | sin datos | |
| Director of Communications | 18.7yrs | sin datos | sin datos | |
| Chief Medical Scientist | less than a year | US$16.34m | sin datos | |
| Head of Toxicology & VP | no data | sin datos | sin datos | |
| Chief Commercial Officer | 1.8yrs | US$2.97m | 0.0073% $ 199.0k | |
| Head of Tax | 2.3yrs | sin datos | sin datos | |
| VP & Treasurer | 2.3yrs | sin datos | sin datos |
5.8yrs
Permanencia media
59yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ARWR es experimentado (5.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 16.3yrs | US$9.92m | 3% $ 82.2m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | sin datos | sin datos | |
| Chairman of the Board | 13.4yrs | US$474.60k | 0.11% $ 3.1m | |
| Independent Lead Director | 12.3yrs | US$459.60k | 0.074% $ 2.0m | |
| Independent Director | 6.3yrs | US$469.60k | 0.027% $ 727.4k | |
| Member of Hepatitis B Clinical Advisory Board | no data | sin datos | sin datos | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 13.7yrs | US$459.60k | 0.037% $ 1.0m | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Hepatitis B Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Hepatitis B Clinical Advisory Board | no data | sin datos | sin datos | |
| Member of Hepatitis B Clinical Advisory Board | no data | sin datos | sin datos |
13.4yrs
Permanencia media
64yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de ARWR son experimentados ( 13.4 años antigüedad media).